

15 December 2025 (day 1)

12.00-13.00	Lunch
13.00-13.05	Greetings and introduction <i>Gianluigi Savarese, Sweden</i>
13.05-14.55	Session 1: Translating guidelines into practice: Status of, barriers to and strategies to foster GDMT implementation <i>Chairs: Camilla Hage, Sweden, Robin Hofmann, Sweden, & Riccardo M. Inciardi, Italy</i>
13.05-13.15	The gap between what guidelines say and what physicians do: The status of GDMT implementation worldwide <i>Felix Lindberg, Sweden</i>
13.15-13.25	Breaking down barriers: The point of view of the nephrologist on worsening renal function during GDMT <i>James Burton, United Kingdom</i>
13.25-13.35	Breaking down barriers: Hyperkalemia – are we reaching a consensus for its management? <i>Gianluigi Savarese, Sweden</i>
13.35-13.45	Breaking down barriers: Hypotension – when is it a real barrier? <i>Nicolas Girerd, France</i>
13.45-13.55	How to secure a fast and safe initiation of GDMT in clinical practice <i>Alexandre Mebazaa, France</i>
13.55-14.05	Worsening HF – which are the available weapons? <i>Marco Metra, Italy</i>
14.05- 14.15	Is there any new GDMT to introduce? Challenging the DIGIT-HF and VICTOR trials <i>Javed Butler, USA</i>
14.15-14.55	Round Table: Ask the experts
14.55-15.10	Coffee Break
15.10-16.30	Session 2: Treating cardio-renal-metabolic disease <i>Chairs: James Burton, United Kingdom, Francesco Cosentino, Sweden & Lars H. Lund, Sweden</i> <i>Discussant: Raffaele Scorsa, Sweden</i>
15.10-15.20	CRM: The sizes of the problem <i>Christian Basile, Sweden</i>
15.20-15.30	Mineralocorticoid receptor: An old and new target for treating CRM <i>Biykem Bozkurt, USA</i>
15.30-15.40	SGLT2i: Targeting T2DM, HF and CKD <i>Javed Butler, USA</i>
15.40-15.50	GLP1Ra: Targeting T2DM, CKD, obesity and HFpEF <i>Mark Petrie, United Kingdom</i>
15.50-16.30	Round Table: Ask the experts
16.30-16.50	Coffee Break

15 December 2025 (day 1)

16.50-17.50 Session 3: Iron deficiency in HF

Chairs: Carin Corovic-Cabrera, Sweden

Discussant: Felix Lindberg, Sweden

16.50-17.00 Iron deficiency in HF: A summary of evidence until 2024

Shelley Zieroth, Canada

17.00-17.10 FAIR-HF2: The last piece of evidence

Stefan D. Anker, Germany

17.10-17.20 Any role for treating iron deficiency in HFpEF

Stephan von Haehling, Germany

17:20-17:30 What is coming next

John Cleland, United Kingdom

17.30-17.50 Round Table: Ask the experts

17.50-18.00 Closure of the day

Gianluigi Savarese, Sweden

16 December 2025 (day 2 - morning)

08.25-08.30	Greetings <i>Gianluigi Savarese, Sweden</i>
08.30-09.30	Session 4: Cardiac amyloidosis <i>Chairs: Carmen Basic, Sweden & Krister Lindmark, Sweden Discussants: Per Eldhagen, Sweden & Riccardo M. Inciardi, Italy</i>
08.30-08.40	How to recognize a patient with cardiac amyloidosis <i>Davide Stolfo, Italy</i>
08.40-08.50	Advances in treatment: current and upcoming therapeutic options <i>Peter van der Meer, The Netherlands</i>
08.50-09.00	Cardiac amyloidosis in clinical practice: Case-based discussion <i>Antonio Cannata, United Kingdom</i>
09.00-09.30	Round Table: Ask the experts
09.30-09.55	Lecture 1: Increasing patient adherence and addressing polypharmacy in patients with HF <i>Chair: Gianluigi Savarese, Sweden; Speaker: Giuseppe Rosano, United Kingdom</i>
09.55-10.15	Coffee Break
10.15-11.45	Session 5: Not only pharmacological treatments: Devices! <i>Chairs: Bahira Shahim, Sweden, Shelley Zieroth, Canada Discussant: Elmir Omerovic, Sweden</i>
10.15-10.25	Primary prophylactic ICD in HF: Towards precision medicine <i>Frieder Braunschweig, Sweden</i>
10.25-10.35	CRT: When is OMT and time to proceed with implantation? <i>Wilfried Mullens, Belgium</i>
10.35-10.45	TR: A treatment target in HF? <i>Marianna Adamo, Italy</i>
10.45-10.55	Treating aortic stenosis in HFrEF: When is it too late or too early? <i>Andreas Rück, Sweden</i>
10.55-11.05	Where do we stand for the treatment of FMR? <i>Marco Metra, Italy</i>
11.05-11.15	What do the new ESC guidelines say? <i>Marianna Adamo, Italy</i>
11.15-11.45	Round Table: Ask the experts
11.45-12.00	Lecture 2: : The evolving epidemiology of HF - what does PORTHOS study teach us? <i>Chair: Riccardo M. Inciardi, Italy; Speaker: Cristina Gavina, Portugal</i>
12.00-13.00	Lunch

Scientific Program

16 December 2025 (day 2 - afternoon)

13.00-13.25

Lecture 3: What can AI do for our HF patients?

Chair: Mitja Lainscak, Slovenia; Speaker: Alicia Uijl, The Netherlands

13.25-14.40

Session 6: Recognizing advanced heart failure: The right timing and the right patients to refer

Chairs: Oscar Braun, Sweden, Ovidiu Chioncel, Romania & Michael Melin, Sweden

Discussant: Lars H. Lund, Sweden

13.25-13.40

How to manage GDMT in advanced HF

Federica Guidetti, Sweden

13.40-13.55

Diuretic resistance in advanced HF: Prevention, recognition, and treatment strategies

Wilfried Mullens, Belgium

13.55-14.10

Selecting the right candidates for transplant, LVAD, or palliative care

Benedikt Schrage, Germany

14.10-14.40

Round Table: Ask the experts

14.40-15.30

Session 7: Hypertrophic cardiomyopathy

Chairs: Mitja Lainscak, Slovenia & Shelley Zieroth, Canada

14.40-14.55

HCM uncovered: From population patterns to precision diagnosis

Antonio Cannata, United Kingdom

14.55-15.10

Treating HCM yesterday, today, and tomorrow

Christian Schulze, Germany

15.10-15.30

Round Table: Ask the experts

15.30-16.00

Lecture 4: Hot off the press and upcoming evidence

Chair: Gianluigi Savarese, Sweden; Speaker: Blykem Bozkurt, USA

16.00-16.05

Closure of the day

Gianluigi Savarese, Sweden